SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 6149.
  • 2
    Boumpas DT, Austin HA III, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 7415.
  • 3
    Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996; 125: 54957.
  • 4
    Illei GG, Austin HA III, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 24857.
  • 5
    Urowitz MB. Is “aggressive” therapy necessary for systemic lupus erythematosus? Rheum Dis Clin North Am 1993; 19: 26370.
  • 6
    Ponticelli C. Treatment of lupus nephritis: the advantages of a flexible approach. Nephrol Dial Transplant 1997; 12: 20579.
  • 7
    Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997; 29: 1939.
  • 8
    Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 3669.
  • 9
    Houssiau FA, D'Cruz DP, Haga H-J, Hughes GRV. Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1991; 1: 315.
  • 10
    D'Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, Lloyd M, et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 1997; 15: 27582.
  • 11
    Haga H-J, D'Cruz D, Asherson R, Hughes GRV. Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 1992; 51: 8858.
  • 12
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 13
    Morel-Maroger LM, Mery JP, Droz D, Godin M, Verroust P, Kourilsky O, et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol Necker Hosp 1976; 6: 79118.
  • 14
    Treasure T. Minimisation: the platinum standard for trials? Br Med J 1998; 317: 3634.
  • 15
    Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al, and The European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992; 10: 5417.
  • 16
    Balow JE, Boumpas DT, Fessler BJ, Austin HA III. Management of lupus nephritis. Kidney Int 1996; 49 Suppl 53: S8892.
  • 17
    Dooley MA, Hogan S, Jennette C, Falk R, for the Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 118895.
  • 18
    Bardsley-Elliot A, Noble S, Foster RH. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation. Biodrugs 1999; 12: 363410.
  • 19
    European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 13215.
  • 20
    Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, et al, for the Mycophenolate Mofetil Investigators. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 50715.
  • 21
    Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, Ji YL, et al, for the Hong Kong–Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 115662.
  • 22
    Dawisha SM, Yarboro CH, Vaughan EM, Austin HA III, Balow JE, Klippel JH. Outpatient monthly oral bolus cyclophosphamide therapy in systemic lupus erythematosus. J Rheumatol 1996; 23: 2738.
  • 23
    McCune WJ. Oral bolus cyclophosphamide: liberating libation or nauseating nostrum? J Rheumatol 1996; 23: 2123.